Skip to main content
OpenTrials
Completed

NCT Number: NCT00612196

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Dose escalation study to assess the safety and tolerability of TB-402, a monoclonal antibody directed against FVIII, versus placebo in healthy male volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Cyncron Clinical Research Unit

Copenhagen, DK-2100, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males 18 to 45 (Groups 1-9) or 55 to 75 (Group 10) years of age
  • No clinically important abnormal physical, laboratory, ECG findings
  • Normal (or abnormal but ncs) supine blood pressure (BP) and heart rate (HR)

Exclusion criteria

  • Self or family history of cardiovascular or pulmonary disorder, coagulation or bleeding disorders or reasonable suspicion of vascular malformations eg cerebral haemorrhage, aneurysm or premature stroke.
  • Any autoimmune disease.
  • Previous allergic reaction to immunoglobulin.
  • Present, or history of, severe allergy, for example asthma or anaphylactic reactions or allergy requiring treatment.
  • Consumption of aspirin, other non-steroidal anti-inflammatory drugs or other drugs known to affect platelet function or any other aspect of coagulation within 14 days before drug administration.
  • Abnormal platelet function or clinically significant out of range values for any coagulation tests.
  • History of important bleeding episodes eg haematemesis, rectal bleeding, severe or recurrent epistaxis, haemoptysis, haematuria or intracranial haemorrhage.
  • Screening FVIII:C < 50%.

Treatment and study plan

TB-402

Drug

Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

Placebo

Drug

Sponsors and collaborators

Lead sponsor

ThromboGenics

Industry

Collaborators

  • BioInvent International AB

Registry information

Official study title

A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers.

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Feb 11, 2008
Registry last updated
Apr 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.